[go: up one dir, main page]

AR061367A1 - CYANOPIRIDINS REPLACED AS INHIBITORS OF PROTEIN QUINASA - Google Patents

CYANOPIRIDINS REPLACED AS INHIBITORS OF PROTEIN QUINASA

Info

Publication number
AR061367A1
AR061367A1 ARP070102592A ARP070102592A AR061367A1 AR 061367 A1 AR061367 A1 AR 061367A1 AR P070102592 A ARP070102592 A AR P070102592A AR P070102592 A ARP070102592 A AR P070102592A AR 061367 A1 AR061367 A1 AR 061367A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkynyl
haloalkyl
alkenyl
aryl
Prior art date
Application number
ARP070102592A
Other languages
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR061367A1 publication Critical patent/AR061367A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula 1 o de formula 2 o una sal, hidrato, o éster farmacéuticamente aceptable del mismo, en donde: X está seleccionado de a) -NR3-Y-, b) -O-Y-, c) -S(O)m-Y-, d) -S(O)mNR3-Y-, e) -NR3S(O)m-Y-, f) -C(O)NR3-Y-, g) - C(S)NR3-Y-, h) -NR3C(O)-Y-, i) -NR3C(S)-Y-, j) -C(O)O-Y-, k) -OC(O)-Y-, y l) un enlace covalente; Y, en cada aparicion, está independientemente seleccionado de a) alquilo C1-10 divalente, b) alquenilo C2-10 divalente, c) alquinilo C2-10 divalente, d) haloalquilo C1-10 divalente, y e) un enlace covalente; R1 es un grupo fenilo opcionalmente sustituido con 1-4 grupos -Y-R4; R2 es arilo C6-14 o heteroarilo de 5-14 miembros, en donde cada grupo está opcionalmente sustituido con 1-4 grupos independientemente seleccionados de -Y-R4 u -O-Y-R4; R3 está seleccionado de a) H, b) alquilo C1-10, c) alquenilo C2-10, d) alquinilo C2-10, y e) grupo haloalquilo C1-10, R4 en cada aparicion, está independientemente seleccionado de a) halogeno, b) - CN, c) -NO2, d) oxo, e) -O-Y-R5, f) -NR6-Y-R7, g) -N(O)R6-Y-R7, h) -S(O)m-Y-R5, i) -S(O)mO-Y-R5, j) -S(O)mNR6-Y-R7, k) -C(O)-Y-R5, l) -C(O)O-Y-R5, m) -C(O)NR6-Y-R7, n) -C(S)NR6-Y-R7, o) alquilo C1-10, p) alquenilo C2-10, q) alquinilo C2-10, r) haloalquilo C1-10, s) cicloalquilo C3-14, t) arilo C6-14, u) cicloheteroalquilo de 3-14 miembros, y v) heteroarilo de 5-14 miembros, en donde cada uno de o) -v) está opcionalmente sustituido con 1-4 grupos -Y-R8; R5, en cada aparicion, está independientemente seleccionado de a) H, b) -C(O)R9, c) -C(O)OR9, d) alquilo C1-10, e) alquenilo C2-10, f) alquinilo C2-10, g) haloalquilo C1-10, h) cicloalquilo C3-14, i) arilo C6-14, j) cicloheteroalquilo de 3-14 miembros, y k) heteroarilo de 5-14 miembros, en donde cada uno de d) - k) está opcionalmente sustituido con 1-4 grupos -Y-R8; R6 y R7, en cada aparicion, están independientemente seleccionados de a) H, b) -O-Y-R9, c) S(O)m-Y-R9, d) -S(O)mO-Y-R9, e) -C(O)-Y-R9, f) -C(O)-Y-R9, g) - C(O)NR10-Y-R11, h) -C(S)NR10-Y-R11, i) alquilo C1-10, j) alquenilo C2-10, k) alquinilo C2-10, l) haloalquilo C1-10, m) cicloalquilo C3-14, n) arilo C6-14, o) cicloheteroalquilo de 3- 14 miembros, y p) heteroarilo de 5-14 miembros; en donde cada uno de i) - p) está opcionalmente sustituido con 1-4 grupos -Y-R8; R8 en cada aparicion, está independientemente seleccionado de a) halogeno, b) -CN, c) -NO2, d) oxo, e) -O-Y-R9, f) -NR10-Y-R11, g) -N(O)R10-Y-R11, h) -S(O)m-Y-R9, i) S(O)mO-Y-R9, j) - S(O)mNR10-Y-R11, k) -C(O)-Y-R9, l) -C(O)O-Y-R9, m) -C(O)NR10-Y-R11, n) -C(S)NR10-Y-R11, o) alquilo C1-10, p) alquenilo C2-10, q) alquinilo C2-10, r) haloalquilo C1-10, s) cicloalquilo C3-14, t) arilo C6-14, u) cicloheteroalquilo de 3-14 miembros, y v) heteroarilo de 5-14 miembros, en donde cada uno de o) -v) está opcionalmente sustituido con 1-4 grupos -Y-R12; R9, en cada aparicion, está independientemente seleccionado de a) H, b) -C(O)-alquilo C1-10, c) -C(O)OH, d) -C(O)O-aIquilo C1-10, e) alquilo C1-10, f) alquenilo C2-10, g) alquinilo C2-10, h) haloalquilo C1-10, i) cicloalquilo C3-14, j) arilo C6-14, k) cicloheteroalquilo de 3-14 miembros, y l) heteroarilo de 5-14 miembros, en donde cada uno de alquilo C1-10, alquenilo C2-10, alquinilo C2-10, haloalquilo C1-10, cicloalquilo C3-14, arilo C6-14, cicloheteroalquilo de 3-14 miembros, y heteroarilo de 5-14 miembros está opcionalmente sustituido con 1-4 grupos -Y-R12, R10 y R11 en cada aparicion, están independientemente seleccionados de a) H, b) -OH, c) -SH, d) -NH2, e) -NH-alquilo C1-10, f) N(alquilo C1-10)2, g) -S(O)m- alquilo C1-10, h) -S(O)2OH, i) -S(O)m-Oalquilo C1-10, j) -C(O)-alquilo C1-10, k) -C(O)OH, l) -C(O)-OaIquilo C1-10, m) -C(O)NH2, n) -C(O)NH- alquiloC1-10, o) -C(O)N(alquilo C1-10)2, p) -C(S)NH2, q) -C(S)NH-alquilo C1-10, r) -C(S)N(alquilo C1-10)2, s) alquilo C1-10, t) alquenilo C2-10, u) alquinilo C2-10, v) alcoxi C1-10, w) haloalquilo C1-10, x) cicloalquilo C3-14, y) arilo C6-14, z) cicloheteroalquilo de 3-14 miembros, y aa) heteroarilo de 5-14 miembros, en donde cada uno de alquilo C1-10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-10, haloalquilo C1-10, cicloalquilo C3-14, arilo C6-14, cicloheteroalquilo de 3-14 miembros, y el heteroarilo de 5-14 miembros está opcionalmente sustituido con 1-4 grupos -Y-R12; R12 en cada aparicion, está independientemente seleccionado de a) halogeno, b) -CN, c) -NO2, d) oxo, e) -OH, f) -NH2, g) -NH(alquilo C1-10), h) -N(alquilo C1-10)2, l) -SH, j) -S(O)m-alquilo C1-10, k) -S(O)2OH, l) -S(O)m- Oalquilo C1-10, m) -C(O)-alquilo C1-10, n) -C(O)OH, o) -C(O)-OalquiIo C1-10, p) -C(O)NH2, q) -C(O)NH-alquilo C1-10, r) -C(O)N(alquilo C1-10)2, s) -C(S)NH2, t) -C(S)NH-alquilo C1-10, u) - C(S)N(alquilo C1-10)2, v) alquilo C1-10, w) alquenilo C2-10, x) alquinilo C2-10, y) alcoxi C1-10, z) haloalquilo C1-10, aa) cicloalquilo C3-14, ab) arilo C6-14, ac) cicloheteroalquilo de 3-14 miembros, y ad) heteroarilo de 5-14 miembros; y m es 0, 1, o 2; siempre que cuando R1 sea un grupo 3-cloro-4-fluorfenilo, R2 no sea un grupo 2-[(1H-imidazol-5-ilmetil)amino]fenilo.Claim 1: A compound of formula 1 or formula 2 or a pharmaceutically acceptable salt, hydrate, or ester thereof, wherein: X is selected from a) -NR3-Y-, b) -OY-, c) -S (O) mY-, d) -S (O) mNR3-Y-, e) -NR3S (O) mY-, f) -C (O) NR3-Y-, g) - C (S) NR3-Y -, h) -NR3C (O) -Y-, i) -NR3C (S) -Y-, j) -C (O) OY-, k) -OC (O) -Y-, and l) a covalent bond ; And, at each occurrence, it is independently selected from a) divalent C1-10 alkyl, b) divalent C2-10 alkenyl, c) divalent C2-10 alkynyl, d) divalent C1-10 haloalkyl, and e) a covalent bond; R1 is a phenyl group optionally substituted with 1-4 -Y-R4 groups; R2 is C6-14 aryl or 5-14 membered heteroaryl, wherein each group is optionally substituted with 1-4 groups independently selected from -Y-R4 or -O-Y-R4; R3 is selected from a) H, b) C1-10 alkyl, c) C2-10 alkenyl, d) C2-10 alkynyl, and e) C1-10 haloalkyl group, R4 at each occurrence, is independently selected from a) halogen, b) - CN, c) -NO2, d) oxo, e) -OY-R5, f) -NR6-Y-R7, g) -N (O) R6-Y-R7, h) -S (O) mY-R5, i) -S (O) mO-Y-R5, j) -S (O) mNR6-Y-R7, k) -C (O) -Y-R5, l) -C (O) OY -R5, m) -C (O) NR6-Y-R7, n) -C (S) NR6-Y-R7, o) C1-10 alkyl, p) C2-10 alkenyl, q) C2-10 alkynyl, r) C1-10 haloalkyl, s) C3-14 cycloalkyl, t) C6-14 aryl, u) 3-14 membered cycloheteroalkyl, and v) 5-14 membered heteroaryl, wherein each of o) -v) is optionally substituted with 1-4 -Y-R8 groups; R5, at each occurrence, is independently selected from a) H, b) -C (O) R9, c) -C (O) OR9, d) C1-10 alkyl, e) C2-10 alkenyl, f) C2 alkynyl -10, g) C1-10 haloalkyl, h) C3-14 cycloalkyl, i) C6-14 aryl, j) 3-14 membered cycloheteroalkyl, and k) 5-14 membered heteroaryl, wherein each of d) - k) is optionally substituted with 1-4 -Y-R8 groups; R6 and R7, in each occurrence, are independently selected from a) H, b) -OY-R9, c) S (O) mY-R9, d) -S (O) mO-Y-R9, e) -C (O) -Y-R9, f) -C (O) -Y-R9, g) - C (O) NR10-Y-R11, h) -C (S) NR10-Y-R11, i) C1 alkyl -10, j) C2-10 alkenyl, k) C2-10 alkynyl, l) C1-10 haloalkyl, m) C3-14 cycloalkyl, n) C6-14 aryl, or) 3-14 membered cycloheteroalkyl, and p) heteroaryl of 5-14 members; wherein each of i) -p) is optionally substituted with 1-4 -Y-R8 groups; R8 at each occurrence, is independently selected from a) halogen, b) -CN, c) -NO2, d) oxo, e) -OY-R9, f) -NR10-Y-R11, g) -N (O) R10-Y-R11, h) -S (O) mY-R9, i) S (O) mO-Y-R9, j) - S (O) mNR10-Y-R11, k) -C (O) - Y-R9, l) -C (O) OY-R9, m) -C (O) NR10-Y-R11, n) -C (S) NR10-Y-R11, o) C1-10 alkyl, p) C2-10 alkenyl, q) C2-10 alkynyl, r) C1-10 haloalkyl, s) C3-14 cycloalkyl, t) C6-14 aryl, u) 3-14 membered cycloheteroalkyl, and v) 5-14 membered heteroaryl , wherein each of o) -v) is optionally substituted with 1-4 -Y-R12 groups; R9, at each occurrence, is independently selected from a) H, b) -C (O) -C1-10 alkyl, c) -C (O) OH, d) -C (O) O-aC1-10 alkyl, e) C1-10 alkyl, f) C2-10 alkenyl, g) C2-10 alkynyl, h) C1-10 haloalkyl, i) C3-14 cycloalkyl, j) C6-14 aryl, k) 3-14 membered cycloheteroalkyl , and l) 5-14 membered heteroaryl, wherein each of C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-10 haloalkyl, C3-14 cycloalkyl, C6-14 aryl, 3-14 cycloheteroalkyl members, and 5-14 member heteroaryl is optionally substituted with 1-4 groups -Y-R12, R10 and R11 in each occurrence, are independently selected from a) H, b) -OH, c) -SH, d) - NH2, e) -NH-C1-10 alkyl, f) N (C1-10 alkyl) 2, g) -S (O) m- C1-10 alkyl, h) -S (O) 2OH, i) -S (O) m-C1-10 alkyl, j) -C (O) -C1-10 alkyl, k) -C (O) OH, l) -C (O) -Oa C1-10 alkyl, m) -C ( O) NH2, n) -C (O) NH- C1-10 alkyl, o) -C (O) N (C1-10 alkyl) 2, p) -C (S) NH2, q) -C (S) NH -C1-10 alkyl, r) -C (S) N (C1-10 alkyl) 2, s) C1-10 alkyl, t) alke C2-10 nyl, u) C2-10 alkynyl, v) C1-10 alkoxy, w) C1-10 haloalkyl, x) C3-14 cycloalkyl, and) C6-14 aryl, z) 3-14 membered cycloheteroalkyl, and aa) 5-14 membered heteroaryl, wherein each of C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-10 alkoxy, C1-10 haloalkyl, C3-14 cycloalkyl, C6-14 aryl, cycloheteroalkyl 3-14 members, and the 5-14 member heteroaryl is optionally substituted with 1-4 -Y-R12 groups; R12 at each occurrence, is independently selected from a) halogen, b) -CN, c) -NO2, d) oxo, e) -OH, f) -NH2, g) -NH (C1-10 alkyl), h) -N (C1-10 alkyl) 2, l) -SH, j) -S (O) m-C1-10 alkyl, k) -S (O) 2OH, l) -S (O) m- C1 -alkyl 10, m) -C (O) -C1-10 alkyl, n) -C (O) OH, or) -C (O) -C1-10 alkyl, p) -C (O) NH2, q) -C (O) NH-C1-10 alkyl, r) -C (O) N (C1-10 alkyl) 2, s) -C (S) NH2, t) -C (S) NH-C1-10 alkyl, or ) - C (S) N (C1-10 alkyl) 2, v) C1-10 alkyl, w) C2-10 alkenyl, x) C2-10 alkynyl, and) C1-10 alkoxy, z) C1-10 haloalkyl, aa) C3-14 cycloalkyl, ab) C6-14 aryl, ac) 3-14 membered cycloheteroalkyl, and ad) 5-14 membered heteroaryl; and m is 0, 1, or 2; provided that when R1 is a 3-chloro-4-fluorphenyl group, R2 is not a 2 - [(1 H -imidazol-5-ylmethyl) amino] phenyl group.

ARP070102592A 2006-06-13 2007-06-13 CYANOPIRIDINS REPLACED AS INHIBITORS OF PROTEIN QUINASA AR061367A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81318206P 2006-06-13 2006-06-13

Publications (1)

Publication Number Publication Date
AR061367A1 true AR061367A1 (en) 2008-08-20

Family

ID=38832510

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102592A AR061367A1 (en) 2006-06-13 2007-06-13 CYANOPIRIDINS REPLACED AS INHIBITORS OF PROTEIN QUINASA

Country Status (12)

Country Link
EP (1) EP2027093A2 (en)
JP (1) JP2009539993A (en)
CN (1) CN101454287A (en)
AR (1) AR061367A1 (en)
AU (1) AU2007258352A1 (en)
BR (1) BRPI0712776A2 (en)
CA (1) CA2650666A1 (en)
CL (1) CL2007001738A1 (en)
MX (1) MX2008015805A (en)
PE (1) PE20080369A1 (en)
TW (1) TW200815356A (en)
WO (1) WO2007146323A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
AU2009279611A1 (en) * 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
CN103408489A (en) * 2013-08-29 2013-11-27 武穴市永宁医药化工有限公司 Preparation method of 3-cyanopyridine oxynitride

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
MXPA05006367A (en) * 2002-12-12 2005-08-29 Pharmacia Corp Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors.
JP2008540656A (en) * 2005-05-18 2008-11-20 ワイス 3-cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same
AR061368A1 (en) * 2006-06-13 2008-08-20 Wyeth Corp 3- CYANOPIRIDINS REPLACED AS INHIBITORS OF PROTEIN QUINASA

Also Published As

Publication number Publication date
CA2650666A1 (en) 2007-12-21
AU2007258352A1 (en) 2007-12-21
MX2008015805A (en) 2009-01-09
WO2007146323A2 (en) 2007-12-21
PE20080369A1 (en) 2008-06-04
CL2007001738A1 (en) 2008-01-18
TW200815356A (en) 2008-04-01
CN101454287A (en) 2009-06-10
BRPI0712776A2 (en) 2013-12-17
WO2007146323A3 (en) 2008-04-17
EP2027093A2 (en) 2009-02-25
JP2009539993A (en) 2009-11-19

Similar Documents

Publication Publication Date Title
AR056200A1 (en) TIENO [2,3-B] PIRIDIN-5-CARBONITRILS AS INHIBITORS OF PROTEIN KINASE
AR066412A1 (en) DERIVATIVES OF DIBENZOFURAN AND DIBENZOTIOPHENE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES IN SUCH PATHOLOGIES SUCH AS OSEOS DISORDERS, TUMORS GROWTH, DIABETES AND OBESITY.
AR071072A1 (en) HYDROXAMATE BASED B DEACETILATE INHIBITORS
PE20080542A1 (en) HEPATITIS C VIRUS INHIBITORS
AR061367A1 (en) CYANOPIRIDINS REPLACED AS INHIBITORS OF PROTEIN QUINASA
CY1113547T1 (en) PROCEDURE FOR COMPOSITION OF USEFUL UNITS IN TREATMENT OF USITIS C
EP2019830A4 (en) INHIBITORS OF SECRETION OF HEPATITIS B VIRUS ANTIGENS FOR THE TREATMENT OF CHRONIC HEPATITIS VIRUS
AR061838A1 (en) THERAPEUTIC PHARMACOCINETIC PROPERTIES MODULATORS
AR066781A1 (en) CINASA INHIBITING IMIDAZOPIRIMIDINE COMPOUNDS
RU2008130925A (en) INHIBITORS
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
DE60142689D1 (en) USE OF PROCARIOTIC PEST-SIMILAR PEPTIDES FOR INCREASING THE IMMUNOGENICITY OF ANTIGENS
AR037656A1 (en) DERIVATIVES OF INDOL AS INHIBITORS OF THE XA FACTOR, A PROCEDURE FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH COMPOUNDS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS
CO5580788A2 (en) BENCIMIDAZOL COMPOUNDS REPLACED USEFUL AS PROTEIN CINASE INHIBITORS
CO6210811A2 (en) ALDH-2 INHIBITORS IN ADDICTION TREATMENT
PE20120258A1 (en) BENZIMIDAZOLE-PYRROLIDINE DERIVATIVES AS INHIBITORS OF HEPATITIS C VIRUS
CO6220855A2 (en) BASED COMPOSITE OF 54-PHENYL-6- (2,2,2-TRIFLUORO-1-PHENYLETOXI) PYRIMIDINE AND METHODS FOR USE
EP1827604A4 (en) METHODS AND COMPOSITIONS FOR ADOPTIVE IMMUNOTHERAPY
PE20221083A1 (en) AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND THEIR METHODS OF USE
PE20080072A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SERINE PROTEASES
EP2084304A4 (en) GALLIUM TRICHLORIDE INJECTION SYSTEM
DE602005008996D1 (en) RADIOFLUORATED PEPTIDES
PE20090216A1 (en) TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS
AR064841A1 (en) COMPOUNDS AND COMPOSITIONS AS AS INHIBITORS OF PROTEASA ACTIVADORA DE CANAL
WO2007036743A3 (en) Quinolines and their therapeutic use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal